News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
800,563 Results
Type
Article (73458)
Company Profile (693)
Press Release (726412)
Section
Business (226831)
Career Advice (3695)
Deals (39192)
Drug Delivery (114)
Drug Development (88928)
Employer Resources (194)
FDA (17712)
Job Trends (17069)
News (386503)
Policy (38613)
Tag
Academia (2974)
Alliances (55500)
Alzheimer's disease (1326)
Approvals (17608)
Artificial intelligence (146)
Bankruptcy (392)
Best Places to Work (12475)
Biotechnology (474)
Breast cancer (122)
Cancer (1056)
Career advice (3145)
Cell therapy (240)
Clinical research (70034)
Collaboration (369)
Compensation (180)
COVID-19 (2796)
C-suite (95)
Data (968)
Diabetes (156)
Diagnostics (6654)
Drug pricing (100)
Earnings (91555)
Employer resources (167)
Events (125264)
Executive appointments (271)
FDA (18201)
Funding (321)
Gene therapy (175)
GLP-1 (683)
Government (4992)
Healthcare (20692)
Infectious disease (2883)
Inflammatory bowel disease (115)
Interviews (721)
IPO (17493)
Job creations (4979)
Job search strategy (2585)
Layoffs (484)
Legal (9836)
Lung cancer (176)
Manufacturing (183)
Medical device (14379)
Medtech (14384)
Mergers & acquisitions (21709)
Metabolic disorders (443)
Neuroscience (1600)
NextGen Class of 2024 (7615)
Non-profit (5061)
Northern California (1343)
Obesity (261)
Opinion (241)
Patents (105)
People (62824)
Pharmaceutical (137)
Phase I (21589)
Phase II (30544)
Phase III (23056)
Pipeline (327)
Postmarket research (3241)
Preclinical (9543)
Radiopharmaceuticals (256)
Rare diseases (214)
Real estate (7115)
Regulatory (25147)
Research institute (2639)
Resumes & cover letters (578)
Southern California (1204)
Startups (4178)
United States (13343)
Vaccines (645)
Weight loss (215)
Date
Last 7 days (1131)
Last 30 days (3382)
Last 365 days (38086)
2024 (33611)
2023 (42565)
2022 (53926)
2021 (58725)
2020 (57668)
2019 (51305)
2018 (39085)
2017 (36829)
2016 (37734)
2015 (43725)
2014 (38362)
2013 (34352)
2012 (36247)
2011 (36361)
2010 (35764)
Location
Africa (1184)
Arizona (203)
Asia (47575)
Australia (8166)
California (3142)
Canada (1227)
China (236)
Colorado (138)
Connecticut (148)
Europe (107564)
Florida (429)
Georgia (115)
Illinois (382)
Indiana (206)
Kansas (102)
Maryland (595)
Massachusetts (2617)
Michigan (165)
Minnesota (281)
New Jersey (920)
New York (916)
North Carolina (806)
Northern California (1343)
Ohio (139)
Pennsylvania (803)
South America (1557)
Southern California (1204)
Texas (443)
Washington State (371)
800,563 Results for "torii pharmaceutical co".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Drug Development
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
Verrica Pharmaceuticals Inc. announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd., reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of Molluscum Contagiosum in Japan.
December 15, 2023
·
4 min read
Biotech Bay
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.
July 1, 2024
·
8 min read
Business
Nogra Pharma announces out-licensing agreement with Torii Pharmaceutical for Japan for New Chemical Entity topical acne treatment
Nogra Pharma today announces it has entered into an out-licensing agreement with Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551), to further develop and commercialise NAC-GED-0507 in Japan for the treatment of acne vulgaris.
January 26, 2023
·
5 min read
Career Advice
How to Deal With a Toxic Co-Worker
Dealing with a toxic co-worker can be exhausting, and it can make your workplace more stressful. There are a few ways to make it easier, including developing healthy coping mechanisms and even talking it out with your colleague.
September 25, 2024
·
5 min read
·
Alina Zahid
Drug Development
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Torii Pharmaceutical Co., Ltd. (“Torii”) dosed the first patient in its Phase 3 trial of VP-102.
August 1, 2022
·
4 min read
Xediton Pharmaceuticals Inc. To Present at The 2024 Bloom Burton & Co. Healthcare Investor Conference
Xediton Pharmaceuticals Inc., a leading Canadian specialty pharmaceutical company, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor
April 9, 2024
·
2 min read
Press Releases
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
October 15, 2024
·
4 min read
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
Eupraxia Pharmaceuticals Inc. announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto.
April 8, 2024
·
6 min read
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Xenon Pharmaceuticals Inc. today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024.
April 10, 2024
·
1 min read
1 of 80,057
Next
